Ask the Expert: Molecular Neurooncology

Question: Molecular Neurooncology: Why is it essential?

Human nervous system tumors, like all cancers, arise from aberration(s) in the molecular controls of normal cellular developmental and biological processes. In essence cancer is a genetic disease, the understanding of which is critical toward improving our capability to diagnose, prognose, develop and select specific biological targeted therapies. In conjunction with non-targeted surgical, radiation and chemotherapy, it is the hoped that rational biological therapies will improve the overall outcome of our patients. These molecular alterations that may arise at the level of DNA, RNA or the proteins themselves, are not singular but rather multiple in human nervous system tumors.

Large scale genomic studies such as The Cancer Genome Atlas (TCGA) and upcoming proteomic based studies have already elucidated that there is much heterogeneity in the molecular profile between nervous system tumors which are pathologically similar. This is even more pronounced between pediatric and their adult counterparts. To complicate further, there likely is regional and temporal heterogeneity as the tumors adapt to different micro-environmental conditions and therapeutic interventions.

The cell of origin of nervous system tumors has created much interest with the relatively recent Cancer Stem Cell (CSC) hypothesis. Previously, cancer was thought to arise from differentiated cells such as astrocytes, with accumulation of genetic alterations. In contrast, the CSC hypothesis stipulates that the cell of origin has stem cell properties of self-renewal and differentiation, which acquires transforming genetic alterations.

The CSC differs from differentiated tumor cells, which form the bulk of the solid tumor, in terms of preferred regions of residing around blood vessels and therapeutic sensitivity. Thereby CSC can serve as a nidus for recurrence. Ongoing debate remains as to which of these model systems of the cell of origin is prevalent in both pediatric and adult nervous system tumors. Likely the answer is a composite of both theories in keeping with the heterogeneity of transformed cells and their adaptability to the tumor microenvironment.

Some of the molecular alterations are germline, either inherited or acquired de-novo, and found in every cell of the body. These inherited syndromes underlie only a small percentage of human nervous system tumors, being more prevalent in pediatric tumors. The molecular understanding of these well defined group of patients, as part of cancer pre-disposition syndromes is important. Often the key molecular alterations in these syndromes are similar to their more common sporadically occurring counterparts. Furthermore, they form the basis of developing model systems such as transgenic mice, to enhance our understanding of the large number of genetic alterations that are being deciphered in sporadic human nervous system tumors and also to provide platforms for therapeutic interventional studies.

In summary, it is essential to understand the molecular biology of nervous system tumors. It is not due to one genetic alteration, but a large number which also evolves as does the tumor. There is already large molecular data sets for adult malignant gliomas and pediatric medulloblastomas, with other nervous system tumors pending. However, what remains the challenge is to determine what are the key molecular alterations and their interactions which “drive” the origin or progression of the tumors vs. those alterations which are secondary and “passengers”. These require experimental paradigms using in vitro and in vitro model systems.
 

 You can download this information as a Brain Tumour Foundation of Canada Information Sheet.
Thank you to Dr. Abhijit Guha, Professor and Senior Scientist at the Hospital for Sick Children (SickKids) in Toronto, Ontario for generously offering his time to provide this interesting information . Dr. Guha also volunteers as a member of Brain Tumour Foundation of Canada’s Professional Advisory Group.

Return to Information Sheets here.

Share This

Featured Story

Kate's Mum's Story

"May 2006 is a month I will never forget. That was the moment that everything became before the cancer, and after the cancer. It was a mark in time that would forever change my family"... Read more about Kate's Mum's story from her diagnosis of glioblastoma in 2006 and how Mum has beaten the odds to still be here today.

Learn more

Spotlight

Roy and the Gamma Knife – A Happy Tale

I had headaches, almost daily, for 10 years or more. It was a rare day if I did not have a headache. I used to joke that I should own...

Learn more

Courtney’s Story of Stability

Stability. It’s a strange concept when you have what it known to be a progressive, life long illness. You hear the words, “Your tumour...

Learn more

Upcoming Events

  • 24/Jul/2018: Groupe de soutien virtuel: Un groupe de soutien virtuel pour personnes touchées par une tumeur... Learn more >
  • 25/Jul/2018: Toronto Support Group: Meets at Wellspring Westerkirk House at Sunnybrook, Toronto, ON... Learn more >
  • 29/Jul/2018: 11th Annual Black Diamond Car Show Presented by Thumbs Up: Black Diamond, AB... Learn more >
  • 02/Aug/2018: Ajax Support Group: Meets at St. Paul's United Church, 65 King's Crescent, Ajax, ON... Learn more >
View All Events >
Thank you to the donors whose contributions make this website and all programs, services and research possible.

Copyright © 2018 Brain Tumour Foundation of Canada. Charitable Registration #BN118816339RR0001